CJC-1295: The GHRH Analog for Sustained Growth Hor…

CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) designed to extend the half-life of natural GHRH and produce sustained elevations in growth hormone (GH) and insulin-like growth factor-1 (IGF-1). It is one of the most widely researched peptides for body composition optimization and anti-aging applications.

What Is CJC-1295?

Natural GHRH has a half-life of only a few minutes due to rapid enzymatic breakdown. CJC-1295 was engineered to resist degradation by replacing certain amino acids vulnerable to dipeptidyl peptidase-IV (DPP-IV) cleavage. This modification extends its half-life dramatically, allowing for more sustained GH stimulation.

There are two main versions: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC. The DAC version binds to albumin in the blood, extending its half-life to approximately 6–8 days, allowing once-weekly dosing. The non-DAC version (also called Modified GRF 1-29 or Mod GRF 1-29) has a half-life of about 30 minutes and is used for acute, pulsatile GH release when combined with a GHRP.

Growth Hormone and IGF-1 Elevation

In clinical trials, CJC-1295 with DAC produced dose-dependent increases in GH levels of 2–10 fold over baseline, with sustained elevation maintained for 6 or more days. IGF-1 increased by 1.5–3 fold and remained elevated for several weeks after the study period ended.

These consistent elevations in GH and IGF-1 drive the cascade of downstream benefits: increased protein synthesis, enhanced fat mobilization, improved recovery, and systemic anabolic signaling throughout the body.

Body Composition Benefits

Higher IGF-1 and GH levels from CJC-1295 translate into meaningful body composition changes over time. Lean muscle mass increases while adipose tissue, particularly visceral fat, decreases. Research participants in clinical trials reported improved body composition over 12-week periods, consistent with the known metabolic effects of elevated GH.

Connective tissue benefits are also notable. GH and IGF-1 promote collagen synthesis, supporting tendon, ligament, and joint health—critical for athletes and aging individuals with accumulated connective tissue wear.

Anti-Aging Applications

The age-related decline of GH (somatopause) contributes to decreased muscle mass, increased fat accumulation, reduced bone density, poorer sleep quality, and cognitive decline. CJC-1295 is one of the most direct pharmacological tools for restoring youthful GH secretion patterns.

Unlike exogenous HGH, which bypasses the pituitary entirely and can suppress natural GH production, CJC-1295 works by stimulating the pituitary through its natural GHRH receptor. This preserves the feedback loop and may reduce the risk of receptor desensitization over time.

CJC-1295 with vs. without DAC

Choosing between the two versions depends on the research goal. CJC-1295 with DAC creates a sustained, relatively flat elevation in GH—analogous to a GH "base." This is useful for general anti-aging and IGF-1 elevation. CJC-1295 without DAC produces sharper, pulsatile GH spikes when combined with a GHRP like GHRP-2 or Ipamorelin, better mimicking natural GH release patterns and potentially providing more selective anabolic and fat-burning effects.

Many protocols combine CJC-1295 without DAC with Ipamorelin for a clean, synergistic GH pulse with minimal side effects from cortisol or prolactin elevation.

Dosing Protocols

CJC-1295 with DAC: 1–2 mg per week via subcutaneous injection. CJC-1295 without DAC: 100–200 mcg per injection, typically 2–3 times per day, often stacked with a GHRP at the same injection time.

Side effects are generally mild and include water retention, tingling, and fatigue, particularly at higher doses. As with all GH secretagogues, monitoring IGF-1 levels is advisable during extended use.

FAQ

Q: What is the difference between CJC-1295 with and without DAC? A: The DAC version has a week-long half-life for sustained GH elevation; the non-DAC version produces pulsatile GH release and is stacked with GHRPs.

Q: Can CJC-1295 replace HGH injections? A: It produces many similar downstream benefits by stimulating natural GH release, but the magnitude differs; it is not a direct replacement for clinical HGH therapy.

Q: Is CJC-1295 safe long-term? A: Human clinical trials showed it to be well-tolerated over 12-week periods; long-term safety data beyond this is limited.

Q: What is the best GHRP to stack with CJC-1295? A: Ipamorelin is the most common pairing for a clean GH pulse; GHRP-2 produces a stronger but less selective response.

Track your supplements in Optimize.

CJC-1295: The GHRH Analog for Sustained Growth Hormone Release